Catatonic or hypotonic immobility induced in mice by intracerebroventricular injection of mu or kappa opioid receptor agonists as well as enkephalins or inhibitors of their degradation

doi:10.1016/0024-3205(83)90334-X

Life Sciences

Volume 33, Issue 21, 21 November 1983, Pages 2105-2111

https://doi.org/10.1016/0024-3205(83)90334-X Get rights and content

Abstract

The intracerebroventricular injections in mice of the mu receptor agonists morphine and fentanyl induced an immobility state (the animals staying motionless with the head down on a 45° inclined plane) which was apparently hypertonic (catatonia ?) or at least enabled them to remain hanging on a horizontal wire with their forepaws. In similar conditions, injections of the kappa receptor agonists ketocyclazocine and bremazocine induced an immobility state which was hypotonic, in contrast with the preceding one. In a similar way to the mu agonists, Met-enkephalin or Leu-enkephalin injected i.c.v. in association with the inhibitor of enkephalinase thiorphan induced an apparently hypertonic immobility which was easily antagonized by naloxone. The association of thiorphan with bestatin ( an inhibitor of aminopeptidases involved in enkephalins inactivation ) produced similar results. In contrast, the hypotonic immobility induced by the kappa receptor agonists required relatively high doses of naloxone to be antagonized. The opiate antagonist MR 2266 antagonized equipotent doses of all the above mentioned agents with a similar efficacy. From these data it is suggested that enkephalins could induce an apparently tonic immobility by stimulating mu receptors and that endogenous enkephalins could be involved in a tonic mediation modulating the locomotor activity or regulating the muscular tone.

References (16)

C. Van Der Wende et al.
Neuropharmacology
(1979)
D. Romer et al.
Life Sciences
(1982)
J.C. Schwartz et al.
Life Sciences
(1981)
S. De La Baume et al.
Neurosciences
(1983)
T.J. Haley et al.
Brit. J. Pharmacol.
(1957)
J.T. Litchfield et al.
J. Pharmacol. exp. Ther.
(1949)
W.R. Martin et al.
J. Pharmacol. exp. Ther.
(1976)
J. Lord et al.
Nature
(1977)

There are more references available in the full text version of this article.

Cited by (24)

In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: Acrylfentanyl, Ocfentanyl and Furanylfentanyl
2022, Neuropharmacology
Citation Excerpt :
Unexpectedly, the grip strength test (Fig. 7) revealed an inhibition of the muscle strength after the injection of all the compounds in a dose-dependent manner and the effect persisted with higher doses (6 and 15 mg/kg) for the whole observation period. The analysis of our results by all the operators shows that the animals were not able to grip the grid and this could be related to hypo-tonicity of the muscles (Chaillet et al., 1983; Weinger et al., 1988; Lui et al., 1989). Indeed, as discussed below, the three opioids induced very important impairment of cardiovascular parameters that could potentially elicit a decrease of muscle strength.
Fentanyl derivatives (FENS) belongs to the class of Novel Synthetic Opioids that emerged in the illegal drug market of New Psychoactive Substances (NPS). These substances have been implicated in many cases of intoxication and death with overdose worldwide. Therefore, the aim of this study is to investigate the pharmaco-dynamic profiles of three fentanyl (FENT) analogues: Acrylfentanyl (ACRYLF), Ocfentanyl (OCF) and Furanylfentanyl (FUF). In vitro, we measured FENS opioid receptor efficacy, potency, and selectivity in calcium mobilization studies performed in cells coexpressing opioid receptors and chimeric G proteins and their capability to promote the interaction of the mu receptor with G protein and β-arrestin 2 in bioluminescence resonance energy transfer (BRET) studies. In vivo, we investigated the acute effects of the systemic administration of ACRYLF, OCF and FUF (0.01–15 mg/kg i.p.) on mechanical and thermal analgesia, motor impairment, grip strength and cardiorespiratory changes in CD-1 male mice. Opioid receptor specificity was investigated in vivo using naloxone (NLX; 6 mg/kg i.p) pre-treatment. In vitro, the three FENS were able to activate the mu opioid receptor in a concentration dependent manner with following rank order potency: FUF > FENT=OCF > ACRYLF. All compounds were able to elicit maximal effects similar to that of dermorphin, with the exception of FUF which displayed lower maximal effects thus behaving as a partial agonist. In the BRET G-protein assay, all compounds behaved as partial agonists for the β-arrestin 2 pathway in comparison with dermorphin, whereas FUF did not promote β-arrestin 2 recruitment, behaving as an antagonist. In vivo, all the compounds increased mechanical and thermal analgesia with following rank order potency ACRYLF = FENT > FUF > OCF and impaired motor and cardiorespiratory parameters. Among the substances tested, FUF showed lower potency for cardiorespiratory and motor effects. These findings reveal the risks associated with the use of FENS and the importance of studying the pharmaco-dynamic properties of these drugs to better understand possible therapeutic interventions in the case of toxicity.
USP8 ameliorates cognitive and motor impairments via microglial inhibition in a mouse model of sepsis-associated encephalopathy
2019, Brain Research
Citation Excerpt :
If the mouse completed the above three parts within 3 s, motor co-ordination was scored as 3 points, whereas if this was completed within 6 s they scored 2 points, or if it took more than 6 s they scored 1 point. This test evaluates the muscle strength of mice (Chaillet et al., 1983). Mice were trained to hang from a horizontal wire by their forepaws and observed for 30 s for a week before CLP.
Sepsis-associated encephalopathy (SAE) is a common and serious complication of sepsis, which is thought to be caused by neuroinflammation. In our previous study, ubiquitin-specific protease 8 (USP8), was reported to regulate inflammation in vitro. In the current study, we investigated whether increased USP8 expression would ameliorate the cognitive and motor impairments induced by cecal ligation and puncture (CLP) in mice, a model of SAE. Male adult mice were randomly divided into four groups: control, sham, CLP, and CLP + USP8 groups. The CLP + USP8 mice showed reduced weight loss on day 4 post-CLP, with a slight increase noted on day 7. The mortality rate in the CLP group was 70% 48 h after CLP; however, USP8 significantly improved survival after CLP. USP8 modulated the neurobehavioral scores in CLP mice. Our results also indicate that USP8 attenuated the CLP-induced cognitive and motor impairments, based on the performance of mice in the Morris water maze (MWM), pole-climbing, and wire suspension tests. USP8 suppressed the release of pro-inflammatory mediators, including prostaglandin E₂ (PGE₂) in the serum and nitric oxide (NO) in brain tissue, as well as levels of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) in brain tissue. Immunofluorescence experiments revealed that USP8 inhibited CLP-induced increases in microglial size and density in the hippocampus, and protected hippocampal neurons. Our findings indicate that neuroinflammation occurs in the brains of CLP mice, and that USP8 exerts protective effects against CLP-induced neuroinflammation and cognitive and motor impairments, which may aid in the development of novel therapeutic strategies for SAE.
Quantitative evaluation of orofacial motor function in mice: The pasta gnawing test, a voluntary and stress-free behavior test
2016, Journal of Neuroscience Methods
Citation Excerpt :
The latency to fall off the wire lid was measured in seconds. A 90 s cut-off time was used (Chaillet et al., 1983). This test assesses motor coordination by placing animals on a rotating rod (four-lane Rota-Rod; Ugo Basile) that runs at a constant or an accelerating speed.
Evaluation of motor deficits in rodents is mostly restricted to limb motor tests that are often high stressors for the animals.
To test rodents for orofacial motor impairments in a stress-free environment, we established the pasta gnawing test by measuring the biting noise of mice that eat a piece of spaghetti. Two parameters were evaluated, the biting speed and the biting peaks per biting episode. To evaluate the power of this test compared to commonly used limb motor and muscle strength tests, three mouse models of Parkinson’s disease, amyotrophic lateral sclerosis and Niemann-Pick disease were tested in the pasta gnawing test, RotaRod and wire suspension test.
Our results show that the pasta gnawing test reliably displays orofacial motor deficits.
The test is especially useful as additional motor test in early onset disease models, since it shows first deficits later than the RotaRod or wire suspension test. The test depends on a voluntary eating behavior of the animal with only a short-time food deprivation and should thus be stress-free.
The pasta gnawing test represents a valuable tool to analyze orofacial motor deficits in different early onset disease models.
Expression of MU, KAPPA, and delta opioid receptor messenger RNA in the human CNS: A <sup>33</sup>P in situ hybridization study
1999, Neuroscience
The existence of at least three opioid receptor types, referred to as μ, κ, and δ, is well established. Complementary DNAs corresponding to the pharmacologically defined μ, κ, and δ opioid receptors have been isolated in various species including man. The expression patterns of opioid receptor transcripts in human brain has not been established with a cellular resolution, in part because of the low apparent abundance of opioid receptor messenger RNAs in human brain. To visualize opioid receptor messenger RNAs we developed a sensitive in situ hybridization histochemistry method using ³³P-labelled RNA probes. In the present study we report the regional and cellular expression of μ, κ, and δ opioid receptor messenger RNAs in selected areas of the human brain. Hybridization of the different opioid receptor probes resulted in distinct labelling patterns. For the μ and κ opioid receptor probes, the most intense regional signals were observed in striatum, thalamus, hypothalamus, cerebral cortex, cerebellum and certain brainstem areas as well as the spinal cord. The most intense signals for the δ opioid receptor probe were found in cerebral cortex. Expression of opioid receptor transcripts was restricted to subpopulations of neurons within most regions studied demonstrating differences in the cellular expression patterns of μ, κ, and δ opioid receptor messenger RNAs in numerous brain regions. The messenger RNA distribution patterns for each opioid receptor corresponded in general to the distribution of opioid receptor binding sites as visualized by receptor autoradiography. However, some mismatches, for instance between μ opioid receptor receptor binding and μ opioid receptor messenger RNA expression in the anterior striatum, were observed. A comparison of the distribution patterns of opioid receptor messenger RNAs in the human brain and that reported for the rat suggests a homologous expression pattern in many regions. However, in the human brain, κ opioid receptor messenger RNA expression was more widely distributed than in rodents.
The differential and region specific expression of opioid receptors may help to identify targets for receptor specific compounds in neuronal circuits involved in a variety of physiological functions including pain perception, neuroendocrine regulation, motor control and reward.
Nociceptin stimulates locomotion and exploratory behaviour in mice
1996, European Journal of Pharmacology
The recently characterized heptadecapeptide nociceptin, the endogenous agonist of the orphan opioid receptor-like 1 (ORL 1 receptor), has been tested for its effects on locomotion and exploratory behaviour in mice. I.c.v. administration of as little as 10 ng of nociceptin/animal stimulated locomotor activity. This effect was dose-dependent, increasing in intensity up to 100 ng and in duration for doses in the range of 1000–10 000 ng. The stimulation of horizontal locomotion elicited by 100 ng nociceptin was accompanied by a stimulation of the vertical component of locomotion. These effects were not reversed by high doses (1.5 and 4.5 mg/kg s.c.) of the opioid receptor antagonist naloxone. Increasing doses of the dopamine D₂ receptor antagonist haloperidol (0.1–0.5 mg/kg i.p.) as well as of the dopamine D₁ receptor antagonist SCH 23390 [R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride] (0.0075–0.03 mg/kg s.c.) reversed this effect, suggesting that nociceptin exerts its motor-stimulant actions by increasing central dopaminergic transmission. Nociceptin was also found to increase the number of head dips in the hole-board test, indicating that the peptide stimulates exploratory behaviour.
Haloperidol-induced catalepsy in mice and rats suppressed by orally pre-administered potentized Agaricus
1995, British Homoeopathic Journal
Agaricus muscarius 30s, a potentized homoeopathic drug prepared by successive dilution and sonication from the alcoholic extract of the fungus of the same name, significantly reduced haloperidol-induced catalepsy in mice and rats. The drug produced the anticataleptic effect when administered orally and no such effect when administered intraperitoneally. Open field activity of the mice was suppressed more with haloperidol (hal) alone than with the combination of Agaricus 30s (oral) and hal. Agaricus 30s, given intraperitoneally, did not alter hal-induced suppression of the spontaneous activity of mice. Based on the previously reported results with Agaricus in combination with apomorphine, D1 and D2 agonists, it was thought that Agaricus might have served as a D1 blocker. It was further assumed that the effect of Agaricus was mediated through the oral taste receptors.

View all citing articles on Scopus

View full text

Catatonic or hypotonic immobility induced in mice by intracerebroventricular injection of mu or kappa opioid receptor agonists as well as enkephalins or inhibitors of their degradation

Abstract

Neuropharmacology

Life Sciences

Life Sciences

Neurosciences

Brit. J. Pharmacol.

J. Pharmacol. exp. Ther.

J. Pharmacol. exp. Ther.

Nature